Marker Therapeutics, Inc. — Director's Dealing 2017

Sep 26, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC. (TPIV)
CIK: 0001094038
Period of Report: 2017-09-22

Reporting Person: WILSON GLYNN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-22	Common Stock	A	100000	$3.18	Acquired	185567	Direct
2017-09-22	Common Stock	F	27350	$3.18	Disposed	158217	Direct

Footnotes

F1: Represents shares of fully vested restricted stock issued under the Company's 2014 Omnibus Stock Ownership Plan in connection with the execution of amendment to employment agreement reflecting change in status from President and Chief Executive Officer to Strategic Advisor.

F2: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the restricted stock award.